Smoke and autoimmunity: The fire behind the disease

Autoimmunity Reviews

Volumn 15, Issue 4, 2016, Pages 354-374

  Perricone, Carlo ^a   Versini, Mathilde ^b   Ben Ami, Dana ^c   Gertel, Smadar ^c   Watad, Abdulla ^c,d   Segel, Michael J ^c,d   Ceccarelli, Fulvia ^a   Conti, Fabrizio ^a   Cantarini, Luca ^e   Bogdanos, Dimitrios P ^f,g   Antonelli, Alessandro ^h   Amital, Howard ^c,d   Valesini, Guido ^a   Shoenfeld, Yehuda ^c,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c SHEBA MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e UNIVERSITY OF SIENA   (Italy)

^f UNIVERSITY OF THESSALY   (Greece)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF PISA   (Italy)

Author keywords

Autoantibodies; Autoimmunity; Epigenetic; Lupus; Smoke; Tobacco

Indexed keywords

ADALIMUMAB; ANTIMALARIAL AGENT; AROMATIC HYDROCARBON; BENZO[A]PYRENE; CIGARETTE SMOKE; CITRULLINE; COLLAGEN TYPE 2; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FIBRINOGEN; FILAGGRIN; HLA DRB1 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MESALAZINE; MESSENGER RNA; NICOTINE; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB; VIMENTIN; AUTOANTIBODY;

AIR POLLUTION; ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE LIVER DISEASE; AUTOIMMUNITY; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CROHN DISEASE; DISEASE PREDISPOSITION; DNA METHYLATION; GENE EXPRESSION; HUMAN; IMMUNOGENICITY; INFECTION; MICROENVIRONMENT; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PATHOGENESIS; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SMOKING; SPONDYLARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THYROIDITIS; ULCERATIVE COLITIS; UPREGULATION; ADVERSE EFFECTS; ANIMAL; IMMUNOLOGY;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; SMOKING;

EID: 84959080034     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.01.001     Document Type: Review

References (430)

1. Shoenfeld Y., Tincani A. Autoantibodies-the smoke and the fire. Autoimmunity 2005, 38(1):1-2.
2. Colafrancesco S., Agmon-Levin N., Perricone C., Shoenfeld Y. Unraveling the soul of autoimmune diseases: pathogenesis, diagnosis and treatment adding dowels to the puzzle. Immunol Res 2013, 56(2-3):200-205.
3. Perricone C., Agmon-Levin N., Ceccarelli F., Valesini G., Anaya J.M., Shoenfeld Y. Genetics and autoantibodies. Immunol Res 2013, 56(2-3):206-219.
4. Meroni P.L., Chighizola C.B., Rovelli F., Gerosa M. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther 2014, 16(2):209.
5. Valesini G., Gerardi M.C., Iannuccelli C., Pacucci V.A., Pendolino M., Shoenfeld Y. Citrullination and autoimmunity. Autoimmun Rev 2015, 14(6):490-497.
6. Strickland F.M., Li Y., Johnson K., Sun Z., Richardson B.C. J CD4(+) T cells epigenetically modified by oxidative stress cause lupus-like autoimmunity in mice. Autoimmunity 2015, 62:75-80. Epub 2015 Jul 9. 10.1016/j.jaut.2015.06.004.
7. Costenbader K.H., Karlson E.W. Cigarette smoking and systemic lupus erythematosus: a smoking gun?. Autoimmunity 2005, 38(7):541-547.
8. Kearley J., Silver J.S., Sanden C., Liu Z., Berlin A.A., White N., et al. Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity 2015, 42(3):566-579.
9. Farhat S.C., Silva C.A., Orione M.A., Campos L.M., Sallum A.M., Braga A.L. Air pollution in autoimmune rheumatic diseases: a review. Autoimmun Rev 2011, 11(1):14-21. Epub 2011 Jul 6. 10.1016/j.autrev.2011.06.008.
10. Essouma M., Noubiap J.J. Is air pollution a risk factor for rheumatoid arthritis?. J Inflamm(Lond) 2015, 12(48). eCollection 2015. 10.1186/s12950-015-0092-1.
11. Astorri E., Nerviani A., Bombardieri M., Pitzalis C. Towards a stratified targeted approach with biologic treatments in rheumatoid arthritis: role of synovial pathobiology. Curr Pharm Des 2015, 21(17):2216-2224.
12. Perricone C., Ceccarelli F., Valesini G. An overview on the genetic of rheumatoid arthritis: a never-ending story. Autoimmun Rev 2011, 10(10):599-608. 10.1016/j.autrev.2011.04.021.
13. Tak P.P., Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000, 43:2619-2633.
14. Raij L., DeMaster E.G., Jaimes E.A. Cigarette smoke-induced endothelium dysfunction: role of superoxide anion. J Hypertens 2001, 19(5). 891-75.
15. Ballanti E., Perricone C., Greco E., Ballanti M., Di Muzio G., Chimenti M.S., et al. Complement and autoimmunity. Immunol Res 2013, 56(2-3):477-491.
16. Di Muzio G., Perricone C., Ballanti E., Kroegler B., Greco E., Novelli L., et al. Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment. Int J Immunopathol Pharmacol 2011, 24(2):357-366.
17. Ballanti E., Perricone C., di Muzio G., Kroegler B., Chimenti M.S., Graceffa D., et al. Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors. Autoimmun Rev 2011, 10(10):617-623. 10.1016/j.autrev.2011.04.012.
18. Symmons D.P., Bankhead C.R., Harrison B.J., Brennan P., Barrett E.M., Scott D.G., et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 1997, 40:1955e61.
19. Nyhall-Wahlin B.M., Jacobsson L.T., Petersson I.F., et al. Smoking is a strong risk factor for rheumatoid nodules in early rheumatoid arthritis. Ann Rheum Dis 2006, 65:601-606.
20. Papadopoulos N.G., Alamanos Y., Voulgari P.V., et al. Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients?. Clin Exp Rheumatol 2005, 23:861-866.
21. Chujo S., Okamoto S., Sunahara R., Adachi M., Yamada K., Hayashi H., et al. Cigarette smoke condensate extracts augment collagen-induced arthritis in mice. Int Immunopharmacol 2010, 10(10):1194-1199. 10.1016/j.intimp.2010.06.026.
22. Kallberg H., Ding B., Padyukov L., Bengtsson C., Ronnelid J., Klareskog L., et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis 2010, 70(3):508-511.
23. Vessey M.P., Villard-Mackintosh L., Yeates D. Oral contraceptives, cigarette smoking and other factors in relation to arthritis. Contraception 1987, 35:457e64.
24. Heliovaara M., Aho K., Aromaa A., Knekt P., Reunanen A. Smoking and risk of rheumatoid arthritis. J Rheumatol 1993, 20:1830e5.
25. Karlson E.W., Lee I.M., Cook N.R., Manson J.E., Buring J.E., Hennekens C.H. A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis Rheum 1999, 42:910e7.
26. Costenbader K.H., Feskanich D., Mandl L.A., Karlson E.W. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med 2006, 119:503e9.
27. Sugiyama D., Nishimura K., Tamaki K., Tsuji G., Nakazawa T., Morinobu A., et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2009.
28. Mattey D.L., Brownfield A., Dawes P.T. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol 2009, 36:1180e7.
29. Saevarsdottir S., Wedrén S., Seddighzadeh M., Bengtsson C., Wesley A., Lindblad S., et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the epidemiological investigation of rheumatoid arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 2011, 63(1):26-36. 10.1002/art.27758.
30. Hutchinson D., Shepstone L., Moots R., Lear J.T., Lynch M.P. Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA. Ann Rheum Dis 2001, 60:223-227.
31. Jaakkola J.J., Gissler M. Maternal smoking in pregnancy as a determinant of rheumatoid arthritis and other inflammatory polyarthropathies during the first 7 years of life. Int J Epidemiol 2005, 34:664-671.
32. Westhoff G., Rau R., Zink A. Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. Rheumatology (Oxford) 2008, 47:849e54.
33. Manfredsdottir V.F., Vikingsdottir T., Jonsson T., et al. The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:734-740.
34. Vesperini V., Lukas C., Fautrel B., Le Loet X., Rincheval N., Combe B. Association of tobacco exposure and reduction of radiographic progression in early rheumatoid arthritis: results from a French multicenter cohort. Arthritis Care Res 2013, 65(12):1899-1906. 10.1002/acr.22057.
35. Finckh A., Dehler S., Costenbader K.H., et al. Cigarette smoking and radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2007, 66:1066-1071.
36. Saag K.G., Cerhan J.R., Kolluri S., et al. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 1997, 56:463-469.
37. Wolfe F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 2000, 27:630-637.
38. Ruiz-Esquide V., Gomez-Puerta J.A., Canete J.D., et al. Effects of smoking on disease activity and radiographic progression in early rheumatoid arthritis. J Rheumatol 2011, 38:2536-2539.
39. Haye Salinas M.J., Retamozo S., Alvarez A.C., Maldonado Ficco H., Dal Pra F., Citera G., et al. Effects of cigarette smoking on early arthritis: a cross-sectional study-data from the Argentine Consortium for Early Arthritis (CONAART). Rheumatol Int 2014, 16.
40. Lee J., Jeong H., Park E.J., Hwang J.W., Bae E.K., Ahn J.K., et al. A role for benzo[a]pyrene and slug in invasive properties of fibroblast-like synoviocytes in rheumatoid arthritis: a potential molecular link between smoking and radiographic progression. Joint Bone Spine 2013, 80(6):621-625. 10.1016/j.jbspin.2013.02.009.
41. Perricone R., de Carolis C., de Sanctis G., Fontana L. Complement activation by cigarette smoke condensate and tobacco infusion. Arch Environ Health 1983, 38(3):176-179.
42. Kurreeman F.A., Padyukov L., Marques R.B., Schrodi S.J., Seddighzadeh M., Stoeken-Rijsbergen G., et al. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis. PLoS Med 2007, 4(9):e278. Erratum in: PLoS Med. 2007 Dec;4(12):e358.
43. Kobayashi S., Okamoto H., Iwamoto T., Toyama Y., Tomatsu T., Yamanaka H., et al. A role for the aryl hydrocarbon receptor and the dioxin TCDD in rheumatoid arthritis. Rheumatology (Oxford) 2008, 47(9):1317-1322. 10.1093/rheumatology/ken259.
44. Henley D.V., Bellone C.J., Williams D.A., et al. Aryl hydrocarbon receptor-mediated posttranscriptional regulation of IL-1beta. Arch Biochem Biophys 2004, 422:42-51.
45. Ospelt C., Camici G.G., Engler A., Kolling C., Vogetseder A., Gay R.E., et al. Smoking induces transcription of the heat shock protein system in the joints. Ann Rheum Dis 2014, 73(7):1423-1426. 10.1136/annrheumdis-2013-204486.
46. Seror R., Le Gall-David S., Bonnaure-Mallet M., Schaeverbeke T., Cantagrel A., Minet J., et al. Anti-Porphyromonas gingivalis antibodies titres are associated with non-smoking status in early rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Rheumatol 2015, 10.1002/art.39118.
47. Mikuls T.R., Payne J.B., Yu F., Thiele G.M., Reynolds R.J., Cannon G.W., et al. Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014, 66(5):1090-1100. 10.1002/art.38348.
48. McInnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365(23):2205-2219. PubMed PMID: 22150039.
49. Vincent C., Nogueira L., Clavel C., Sebbag M., Serre G. Autoantibodies to citrullinated proteins: ACPA. Autoimmunity 2005, 38(1):17-24. PubMed PMID: 15804701.
50. Vincent C., Nogueira L., Sebbag M., Chapuy-Regaud S., Arnaud M., Letourneur O., et al. Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis. Arthritis Rheum 2002, 46(8):2051-2058. PubMed PMID: 12209508.
51. Nishimura K., Sugiyama D., Kogata Y., Tsuji G., Nakazawa T., Kawano S., et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007, 146(11):797-808. PubMed PMID: 17548411.
52. Avouac J., Gossec L., Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006, 65(7):845-851. PubMed PMID: 16606649. Pubmed Central PMCID:1798205.
53. van Venrooij W.J., van Beers J.J., Pruijn G.J. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 2011, 7(7):391-398. PubMed PMID: 21647203.
54. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62(9):2569-2581. PubMed PMID: 20872595.
55. Nielen M.M., van Schaardenburg D., Reesink H.W., van de Stadt R.J., van der Horst-Bruinsma I.E., de Koning M.H., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50(2):380-386. PubMed PMID: 14872479.
56. Meyer O., Labarre C., Dougados M., Goupille P., Cantagrel A., Dubois A., et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003, 62(2):120-126. PubMed PMID: 12525380. Pubmed Central PMCID: 1754441.
57. Foulquier C., Sebbag M., Clavel C., Chapuy-Regaud S., Al Badine R., Mechin M.C., et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 2007, 56(11):3541-3553. PubMed PMID: 17968929.
58. Simon M., Girbal E., Sebbag M., Gomes-Daudrix V., Vincent C., Salama G., et al. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis. J Clin Invest 1993, 92(3):1387-1393. PubMed PMID: 7690781. Pubmed Central PMCID: 288281.
59. Turunen S., Koivula M.K., Melkko J., Alasaarela E., Lehenkari P., Risteli J. Different amounts of protein-bound citrulline and homocitrulline in foot joint tissues of a patient with anti-citrullinated protein antibody positive erosive rheumatoid arthritis. J Transl Med 2013, 11:224. PubMed PMID: 24060405. Pubmed Central PMCID: 3848878.
60. Uysal H., Nandakumar K.S., Kessel C., Haag S., Carlsen S., Burkhardt H., et al. Antibodies to citrullinated proteins: molecular interactions and arthritogenicity. Immunol Rev 2010, 233(1):9-33. PubMed PMID: 20192990.
61. Snir O., Rieck M., Gebe J.A., Yue B.B., Rawlings C.A., Nepom G., et al. Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1*0401-positive humanized mice and rheumatoid arthritis patients. Arthritis Rheum 2011, 63(10):2873-2883. PubMed PMID: 21567378. Pubmed Central PMCID: 3174345.
62. Suzuki A., Yamada R., Chang X., Tokuhiro S., Sawada T., Suzuki M., et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003, 34(4):395-402. PubMed PMID: 12833157.
63. Auger I., Sebbag M., Vincent C., Balandraud N., Guis S., Nogueira L., et al. Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen. Arthritis Rheum 2005, 52(11):3424-3432. PubMed PMID: 16255019.
64. Gonzalez-Gay M.A., Garcia-Porrua C., Hajeer A.H. Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Semin Arthritis Rheum 2002, 31(6):355-360. PubMed PMID: 12077707.
65. Gregersen P.K., Silver J., Winchester R.J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987, 30(11):1205-1213. PubMed PMID: 2446635.
66. Hill J.A., Southwood S., Sette A., Jevnikar A.M., Bell D.A., Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003, 171(2):538-541. PubMed PMID: 12847215.
67. Law S.C., Street S., Yu C.H., Capini C., Ramnoruth S., Nel H.J., et al. T-cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients carrying HLA-DRB1 shared epitope alleles. Arthritis Res Ther 2012, 14(3):R118. PubMed PMID: 22594821. Pubmed Central PMCID: 3446499.
68. van der Helm-van Mil A.H., Verpoort K.N., Breedveld F.C., Huizinga T.W., Toes R.E., de Vries R.R. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 2006, 54(4):1117-1121. PubMed PMID: 16572446.
69. Linn-Rasker S.P., van der Helm-van Mil A.H., van Gaalen F.A., Kloppenburg M., de Vries R.R., le Cessie S., et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2006, 65(3):366-371. PubMed PMID: 16014670. Pubmed Central PMCID: 1798061.
70. Makrygiannakis D., Af Klint E., Lundberg I.E., Lofberg R., Ulfgren A.K., Klareskog L., et al. Citrullination is an inflammation-dependent process. Ann Rheum Dis 2006, 65(9):1219-1222. PubMed PMID: 16540548. Pubmed Central PMCID: 1798285.
71. Makrygiannakis D., Hermansson M., Ulfgren A.K., Nicholas A.P., Zendman A.J., Eklund A., et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 2008, 67(10):1488-1492. PubMed PMID: 18413445.
72. Hill J.A., Bell D.A., Brintnell W., Yue D., Wehrli B., Jevnikar A.M., et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 2008, 205(4):967-979. PubMed PMID: 18391064. Pubmed Central PMCID: 2292232.
73. Klareskog L., Stolt P., Lundberg K., Kallberg H., Bengtsson C., Grunewald J., et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006, 54(1):38-46. PubMed PMID: 16385494.
74. Lee Y.H., Rho Y.H., Choi S.J., Ji J.D., Song G.G., Nath S.K., et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases-a meta-analysis. Rheumatology 2007, 46(1):49-56. PubMed PMID: 16760194.
75. Turesson C., Jacobsson L.T. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2004, 33(2):65-72. PubMed PMID: 15163106.
76. Harel-Meir M., Sherer Y., Shoenfeld Y. Tobacco smoking and autoimmune rheumatic diseases. Nat Clin Pract Rheumatol 2007, 3(12):707-715. PubMed PMID: 18037930.
77. Ruiz-Esquide V., Gomara M.J., Peinado V.I., Gomez Puerta J.A., Barbera J.A., Canete Jde D., et al. Anti-citrullinated peptide antibodies in the serum of heavy smokers without rheumatoid arthritis. A differential effect of chronic obstructive pulmonary disease?. Clin Rheumatol 2012, 31(7):1047-1050. PubMed PMID: 22466712.
78. Costenbader K.H., Karlson E.W. Cigarette smoking and autoimmune disease: what can we learn from epidemiology?. Lupus 2006, 15(11):737-745. PubMed PMID: 17153844.
79. Bracke K.R., D'Hulst A.I., Maes T., Moerloose K.B., Demedts I.K., Lebecque S., et al. Cigarette smoke-induced pulmonary inflammation and emphysema are attenuated in CCR6-deficient mice. J Immunol 2006, 177(7):4350-4359. PubMed PMID: 16982869.
80. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002, 2(5):372-377. PubMed PMID: 12033743.
81. Churg A., Dai J., Tai H., Xie C., Wright J.L. Tumor necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown. Am J Respir Crit Care Med 2002, 166(6):849-854. PubMed PMID: 12231496.
82. Chung S., Sundar I.K., Hwang J.W., Yull F.E., Blackwell T.S., Kinnula V.L., et al. NF-kappaB inducing kinase, NIK mediates cigarette smoke/TNFalpha-induced histone acetylation and inflammation through differential activation of IKKs. PLoS One 2011, 6(8). PubMed PMID: 21887257. Pubmed Central PMCID: 3160853.
83. Heijink I.H., Pouwels S.D., Leijendekker C., de Bruin H.G., Zijlstra G.J., van der Vaart H., et al. Cigarette smoke induced DAMP release from necrotic neutrophils triggers pro-inflammatory mediator release. Am J Respir Cell Mol Biol 2014, 5. PubMed PMID: 25192219.
84. Lee J., Taneja V., Vassallo R. Cigarette smoking and inflammation: cellular and molecular mechanisms. J Dent Res 2012, 91(2):142-149. PubMed PMID: 21876032. Pubmed Central PMCID: 3261116.
85. Pulling L.C., Vuillemenot B.R., Hutt J.A., Devereux T.R., Belinsky S.A. Aberrant promoter hypermethylation of the death-associated protein kinase gene is early and frequent in murine lung tumors induced by cigarette smoke and tobacco carcinogens. Cancer Res 2004, 64(11):3844-3848. PubMed PMID: 15172992.
86. Hodge S., Hodge G., Holmes M., Reynolds P.N. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J 2005, 25(3):447-454. PubMed PMID: 15738287.
87. Vassallo R., Luckey D., Behrens M., Madden B., Luthra H., David C., et al. Cellular and humoral immunity in arthritis are profoundly influenced by the interaction between cigarette smoke effects and host HLA-DR and DQ genes. Clin Immunol 2014, 152(1-2):25-35. PubMed PMID: 24631425. Pubmed Central PMCID: 4004713.
88. Rangel-Moreno J., Hartson L., Navarro C., Gaxiola M., Selman M., Randall T.D. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest 2006, 116(12):3183-3194. PubMed PMID: 17143328. Pubmed Central PMCID: 1678820.
89. Reynisdottir G., Karimi R., Joshua V., Olsen H., Hensvold A.H., Harju A., et al. Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol 2014, 66(1):31-39. PubMed PMID: 24449573.
90. Morissette M.C., Jobse B.N., Thayaparan D., Nikota J.K., Shen P., Labiris N.R., et al. Persistence of pulmonary tertiary lymphoid tissues and anti-nuclear antibodies following cessation of cigarette smoke exposure. Respir Res 2014, 15:49. PubMed PMID: 24754996. Pubmed Central PMCID: 4021094.
91. Mannino D.M., Homa D.M., Akinbami L.J., Ford E.S., Redd S.C. Chronic obstructive pulmonary disease surveillance--United States, 1971-2000. Respir Care 2002, 47(10):1184-1199. PubMed PMID: 12354338.
92. Shen T.C., Lin C.L., Chen C.H., Tu C.Y., Hsia T.C., Shih C.M., et al. Increased risk of chronic obstructive pulmonary disease in patients with rheumatoid arthritis: a population-based cohort study. QJM 2014, 107(7):537-543. PubMed PMID: 24497528.
93. Bieber V., Cohen A.D., Freud T., Agmon-Levin N., Gertel S., Amital H. Autoimmune smoke and fire-coexisting rheumatoid arthritis and chronic obstructive pulmonary disease: a cross-sectional analysis. Immunol Res 2013, 56(2-3):261-266. PubMed PMID: 23568054.
94. Agusti A., MacNee W., Donaldson K., Cosio M. Hypothesis: does COPD have an autoimmune component?. Thorax 2003, 58(10):832-834. PubMed PMID: 14514931. Pubmed Central PMCID: 1746486.
95. Cosio M.G., Saetta M., Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009, 360(23):2445-2454. PubMed PMID: 19494220.
96. Lane N., Robins R.A., Corne J., Fairclough L. Regulation in chronic obstructive pulmonary disease: the role of regulatory T-cells and Th17 cells. Clin Sci 2010, 119(2):75-86. PubMed PMID: 20402669.
97. Zhang M.Q., Wan Y., Jin Y., Xin J.B., Zhang J.C., Xiong X.Z., et al. Cigarette smoking promotes inflammation in patients with COPD by affecting the polarization and survival of Th/Tregs through up-regulation of muscarinic receptor 3 and 5 expression. PLoS One 2014, 9(11). PubMed PMID: 25375131. Pubmed Central PMCID: 4223024.
98. Karsdal M.A., Henriksen K., Leeming D.J., Woodworth T., Vassiliadis E., Bay-Jensen A.C. Novel combinations of post-translational modification (PTM) neo-epitopes provide tissue-specific biochemical markers-are they the cause or the consequence of the disease?. Clin Biochem 2010, 43(10-11):793-804. PubMed PMID: 20381482.
99. Harries A.D., Baird A., Rhodes J. Non-smoking: a feature of ulcerative colitis. Br Med J 1982, 284:706.
100. Somerville K.W., Logan R.F., Edmond M., Langman M.J. Smoking and Crohn's disease. Br Med J 1984, 289:954-956.
101. Nos P., Domenech E. Management of Crohn's disease in smokers: is an alternative approach necessary?. World J Gastroenterol 2011, 17:3567-3574.
102. Calkins B.M. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989, 34:1841-1854.
103. Karban A., Eliakim R. Effect of smoking on inflammatory bowel disease: is it disease or organ specific?. World J Gastroenterol 2007, 13:2150-2152.
104. Mahid S.S., Minor K.S., Soto R.E., Hornung C.A., Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006, 81:1462-1471.
105. Birrenbach T., Bocker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis 2004, 10:848-859.
106. Verschuere S., De Smet R., Allais L., Cuvelier C.A. The effect of smoking on intestinal inflammation: what can be learned from animal models?. J Crohns Colitis 2012, 6:1-12.
107. Probert C.S., Jayanthi V., Hughes A.O., Thompson J.R., Wicks A.C., Mayberry J.F. Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and south Asians in Leicestershire. Gut 1993, 34:1547-1551.
108. Reddy S.I., Burakoff R. Inflammatory bowel disease in African Americans. Inflamm Bowel Dis 2003, 9:380-385.
109. Reif S., Klein I., Arber N., Gilat T. Lack of association between smoking and inflammatory bowel disease in Jewish patients in Israel. Gastroenterology 1995, 108:1683-1687.
110. Ben-Horin S., Avidan B., Yanai H., Lang A., Chowers Y., Bar-Meir S. Familial clustering of Crohn's disease in Israel: prevalence and association with disease severity. Inflamm Bowel Dis 2009, 15:171-175.
111. McGilligan V.E., Wallace J.M., Heavey P.M., Ridley D.L., Rowland I.R. Hypothesis about mechanisms through which nicotine might exert its effect on the interdependence of inflammation and gut barrier function in ulcerative colitis. Inflamm Bowel Dis 2007, 13:108-115.
112. Galeazzi F., Blennerhassett P.A., Qiu B., O'Byrne P.M., Collins S.M. Cigarette smoke aggravates experimental colitis in rats. Gastroenterology 1999, 117:877-883.
113. Eliakim R., Karmeli F. Divergent effects of nicotine administration on cytokine levels in rat small bowel mucosa, colonic mucosa, and blood. Isr Med Assoc J 2003, 5:178-180.
114. Eliakim R., Karmeli F., Cohen P., Heyman S.N., Rachmilewitz D. Dual effect of chronic nicotine administration: augmentation of jejunitis and amelioration of colitis induced by iodoacetamide in rats. Int J Colorectal Dis 2001, 16:14-21.
115. Beltran B., Nos P., Dasi F., Iborra M., Bastida G., Martinez M., et al. Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naive and treated Crohn's disease. Inflamm Bowel Dis 2010, 16:76-86.
116. Kalra J., Chaudhary A.K., Prasad K. Increased production of oxygen free radicals in cigarette smokers. Int J Exp Pathol 1991, 72:1-7.
117. Prytz H., Benoni C., Tagesson C. Does smoking tighten the gut?. Scand J Gastroenterol 1989, 24:1084-1088.
118. Wang H., Zhao J.X., Hu N., Ren J., Du M., Zhu M.J. Side-stream smoking reduces intestinal inflammation and increases expression of tight junction proteins. World J Gastroenterol 2012, 18:2180-2187.
119. Nielsen O.H., Bjerrum J.T., Csillag C., Nielsen F.C., Olsen J. Influence of smoking on colonic gene expression profile in Crohn's disease. PLoS One 2009, 4.
120. Holdstock G., Savage D., Harman M., Wright R. Should patients with inflammatory bowel disease smoke?. Br Med J 1984, 288:362.
121. Timmer A., Sutherland L.R., Martin F. Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1998, 114:1143-1150.
122. Mahid S.S., Minor K.S., Stevens P.L., Galandiuk S. The role of smoking in Crohn's disease as defined by clinical variables. Dig Dis Sci 2007, 52:2897-2903.
123. Ashley M.J. Smoking and diseases of the gastrointestinal system: an epidemiological review with special reference to sex differences. Can J Gastroenterol 1997, 11:345-352. = Journal canadien de gastroenterologie.
124. Lakatos P.L., Szamosi T., Lakatos L. Smoking in inflammatory bowel diseases: good, bad or ugly?. World J Gastroenterol 2007, 13:6134-6139.
125. Arnott I.D., McNeill G., Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003, 17:1451-1457.
126. Parsi M.A., Achkar J.P., Richardson S., Katz J., Hammel J.P., Lashner B.A., et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002, 123:707-713.
127. Orlando A., Colombo E., Kohn A., Biancone L., Rizzello F., Viscido A., et al. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Stud Liver 2005, 37:577-583.
128. Fefferman D.S., Lodhavia P.J., Alsahli M., Falchuk K.R., Peppercorn M.A., Shah S.A., et al. Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. Inflamm Bowel Dis 2004, 10:346-351.
129. Johnson G.J., Cosnes J., Mansfield J.C. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther 2005, 21:921-931.
130. Hoie O., Wolters F., Riis L., Aamodt G., Solberg C., Bernklev T., et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007, 102:1692-1701.
131. Boyko E.J., Perera D.R., Koepsell T.D., Keane E.M., Inui T.S. Effects of cigarette smoking on the clinical course of ulcerative colitis. Scand J Gastroenterol 1988, 23:1147-1152.
132. van der Heide F., Dijkstra A., Weersma R.K., Albersnagel F.A., van der Logt E.M., Faber K.N., et al. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2009, 15:1199-1207.
133. Bastida G., Beltran B. Ulcerative colitis in smokers, non-smokers and ex-smokers. World J Gastroenterol 2011, 17:2740-2747.
134. Fraga X.F., Vergara M., Medina C., Casellas F., Bermejo B., Malagelada J.R. Effects of smoking on the presentation and clinical course of inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997, 9:683-687.
135. Aldhous M.C., Drummond H.E., Anderson N., Baneshi M.R., Smith L.A., Arnott I.D., et al. Smoking habit and load influence age at diagnosis and disease extent in ulcerative colitis. Am J Gastroenterol 2007, 102:589-597.
136. Merrett M.N., Mortensen N., Kettlewell M., Jewell D.O. Smoking may prevent pouchitis in patients with restorative proctocolectomy for ulcerative colitis. Gut 1996, 38:362-364.
137. Motley R.J., Rhodes J., Kay S., Morris T.J. Late presentation of ulcerative colitis in ex-smokers. Int J Colorectal Dis 1988, 3:171-175.
138. Srivasta E.D., Newcombe R.G., Rhodes J., Avramidis P., Mayberry J.F. Smoking and ulcerative colitis: a community study. Int J Colorectal Dis 1993, 8:71-74.
139. Lunney P.C., Leong R.W. Review article: ulcerative colitis, smoking and nicotine therapy. Aliment Pharmacol Ther 2012, 36:997-1008.
140. McGrath J., McDonald J.W., McDonald J.K. Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2004.
141. Nikfar S., Ehteshami-Ashar S., Rahimi R., Abdollahi M. Systematic review and meta-analysis of the efficacy and tolerability of nicotine preparations in active ulcerative colitis. Clin Ther 2010, 32:2304-2315.
142. Ward M.M. Predictors of the progression of functional disability in patients with ankylosing spondylitis. J Rheumatol 2002, 29:1420-1425.
143. Averns H.L., Oxtoby J., Taylor H.G., Jones P.W., Dziedzic K., Dawes P.T. Smoking and outcome in ankylosing spondylitis. Scand J Rheumatol 1996, 25:138-142.
144. Chung H.Y., Machado P., van der Heijde D., D'Agostino M.A., Dougados M. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis 2012, 71:809-816.
145. Koko V., Ndrepepa A., Skënderaj S., Ploumis A., Backa T., Tafaj A. An epidemiological study on ankylosing spondylitis in southern Albania. Mater Sociomed 2014, 26:26-29.
146. Mattey D.L., Dawson S.R., Healey E.L., Packham J.C. Relationship between smoking and patient-reported measures of disease outcome in ankylosing spondylitis. J Rheumatol 2011, 38:2608-2615.
147. Kaan U., Ferda O. Evaluation of clinical activity and functional impairment in smokers with ankylosing spondylitis. Rheumatol Int 2005, 25:357-360.
148. Doran M.F., Brophy S., MacKay K., Taylor G., Calin A. Predictors of longterm outcome in ankylosing spondylitis. J Rheumatol 2003, 30:316-320.
149. Ward M.M., Weisman M.H., Davis J.C., Reveille J.D. Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum 2005, 53:710-717.
150. Bodur H., Ataman S., Rezvani A., Buğdayci D.S., Cevik R., Birtane M., et al. Quality of life and related variables in patients with ankylosing spondylitis. Qual Life Res 2011, 20:543-549.
151. Haglund E., Petersson I.F., Bremander A., Bergman S. Predictors of presenteeism and activity impairment outside work in patients with spondyloarthritis. J Occup Rehabil 2014, [Epub ahead of print].
152. Boonen A., Boone C., Albert A., Mielants H. Understanding limitations in at-work productivity in patients with active ankylosing spondylitis: the role of work-related contextual factors. J Rheumatol 2015, 42:93-100.
153. Ward M.M., Hendrey M.R., Malley J.D., Learch T.J., Davis J.C., Reveille J.D., et al. Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Rheum 2009, 61:859-866.
154. Poddubnyy D., Haibel H., Listing J., Märker-Hermann E., Zeidler H., Braun J., et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012, 64:1388-1398.
155. Poddubnyy D., Haibel H., Listing J., Märker-Hermann E., Zeidler H., Braun J., et al. Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the German SPondyloarthritis Inception rohort (GESPIC). Ann Rheum Dis 2013, 72:1430-1432.
156. Videm V., Cortes A., Thomas R., Brown M.A. Current smoking is associated with incident ankylosing spondylitis - the HUNT population-based Norwegian health study. J Rheumatol 2014, 41:2041-2048.
157. Ciurea A., Finckh A. Smoking and spondyloarthritis. Joint Bone Spine 2013, 80:234-235.
158. Reed M.D., Dharmage S., Boers A., Martin B.J., Buchanan R.R., Schachna L. Ankylosing spondylitis: an Australian experience. Intern Med J 2008, 38:321-327.
159. Dincer U., Cakar E., Kiralp M.Z., Bozkanat E., Kilac H., Dursun H. The pulmonary involvement in rheumatic diseases: pulmonary effects of ankylosing spondylitis and its impact on functionality and quality of life. Tohoku J Exp Med 2007, 212:423-430.
160. Jadon D., Shaddick G., Jobling A., Ramanan A.V., Sengupta R. Clinical outcomes and progression to orthopedic surgery in juvenile versus adult-onset ankylosing spondylitis. Arthritis Care Res 2014, [Epub ahead of print].
161. Kydd A.S., Chen J.S., Makovey J., Chand V., Henderson L., Buchbinder R., et al. Smoking did not modify the effects of anti-TNF treatment on health-related quality of life among Australian ankylosing spondylitis patients. Rheumatology (Oxford) 2014, [Epub ahead of print].
162. Kimball A.B., Leonardi C., Stahle M., Gulliver W., Chevrier M., Fakharzadeh S., et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol 2014, 171:137-147.
163. Hayes J., Koo J. Psoriasis: depression, anxiety, smoking, and drinking habits. Dermatol Ther 2010, 23:174-180.
164. Guenther L., Gulliver W. Psoriasis comorbidities. J Cutan Med Surg 2009, 13:S77-S87.
165. Helmick C.G., Lee-Han H., Hirsch S.C., Baird T.L., Bartlett C.L. Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys. Am J Prev Med 2014, 47:37-45.
166. Fortes C., Mastroeni S., Leffondré K., Sampogna F., Melchi F., Mazzotti E., et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 2005, 141:1580-1584.
167. Armstrong A.W., Harskamp C.T., Dhillon J.S., Armstrong E.J. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol 2014, 170:304-314.
168. Asokan N., Prathap P., Rejani P. Severity of psoriasis among adult males is associated with smoking, not with alcohol use. Indian J Dermatol 2014, 59:237-240.
169. Debniak T., Soczawa E., Boer M., Rózewicka-Czabańska M., Wiśniewska J., Serrano-Fernandez P., et al. Common variants of ZNF750, RPTOR and TRAF3IP2 genes and psoriasis risk. Arch Dermatol Res 2014, 306:231-238.
170. Setty A.R., Curhan G., Choi H.K. Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med 2007, 120:953-959.
171. Wolkenstein P., Revuz J., Roujeau J.C., Bonnelye G., Grob J.J., Bastuji-Garin S., et al. Psoriasis in France and associated risk factors: results of a case-control study based on a large community survey. Dermatology 2009, 218:103-109.
172. Naldi L., Peli L., Parazzini F. Association of early-stage psoriasis with smoking and male alcohol consumption: evidence from an Italian case-control study. Arch Dermatol 1999, 135:1479-1484.
173. Poikolainen K., Reunala T., Karvonen J. Smoking, alcohol and life events related to psoriasis among women. Br J Dermatol 1994, 130:473-477.
174. Li W., Han J., Choi H.K., Qureshi A.A. Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am J Epidemiol 2012, 175:402-413.
175. Gerdes S., Zahl V.A., Weichenthal M., Mrowietz U. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology 2010, 220:38-43.
176. Jin Y., Yang S., Zhang F., Kong Y., Xiao F., Hou Y., et al. Combined effects of HLA-Cw6 and cigarette smoking in psoriasis vulgaris: a hospital-based case-control study in China. J Eur Acad Dermatol Venereol 2009, 23:132-137.
177. Mills C.M., Srivastava E.D., Harvey I.M., Swift G.L., Newcombe R.G., Holt P.J., et al. Smoking habits in psoriasis: a case control study. Br J Dermatol 1992, 127:18-21.
178. Naldi L., Parazzini F., Brevi A., Peserico A., Veller Fornasa C., Grosso G., et al. Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol 1992, 127:212-217.
179. Zhu K.J., Quan C., Zhang C., Liu Z., Liu H., Li M., et al. Combined effect between CHRNB3-CHRNA6 region gene variant (rs6474412) and smoking in psoriasis vulgaris severity. Gene 2014, 544:123-127.
180. Di Lernia V., Ricci C., Lallas A., Ficarelli E. Clinical predictors of nonresponse to any tumor necrosis factor (TNF) blockers: a retrospective study. J Dermatolog Treat 2014, 25:73-74.
181. Umezawa Y., Saeki H., Nakagawa H. Some clinical factors affecting quality of the response to ustekinumab for psoriasis. J Dermatol 2014, 41:690-696.
182. Serwin A.B., Sokolowska M., Chodynicka B. Tumor necrosis factor-alpha-converting enzyme as a potential mediator of the influence of smoking on the response to treatment with narrowband ultraviolet B in psoriasis patients. Photodermatol Photoimmunol Photomed 2010, 26:36-40.
183. Kinahan C.E., Mazloom S., Fernandez A.P. Impact of smoking on response to systemic treatment in patients with psoriasis: a retrospective case-control study. Br J Dermatol 2014, [Epub ahead of print]. 10.1111/bjd.13359.
184. Staples J., Klein D. Can nicotine use alleviate symptoms of psoriasis?. Can Fam Physician 2012, 58:404-408.
185. Gómez-Fernández C., Herranz Pinto P., Casado Verrier B., Sendagorta Cudós E., Beato-Merino M.J., Jiménez M.C. Drug eruption and exacerbation of psoriasis related to bupropion. Eur J Dermatol 2011, 21:120-121.
186. Gelfand J.M., Gladman D.D., Mease P.J., Smith N., Margolis D.J., Nijsten T., et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005, 53:573.
187. Tey H.L., Ee H.L., Tan A.S., Theng T.S., Wong S.N., Khoo S.W. Risk factors associated with having psoriatic arthritis in patients with cutaneous psoriasis. J Dermatol 2010, 37:426-430.
188. Pattison E., Harrison B.J., Griffiths C.E., Silman A.J., Bruce I.N. Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Ann Rheum Dis 2008, 67:672-676.
189. Duffin K.C., Freeny I.C., Schrodi S.J., Wong B., Feng B.J., Soltani-Arabshahi R., et al. Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking. J Invest Dermatol 2009, 129:2777-2783.
190. Eder L., Law T., Chandran V., Shanmugarajah S., Shen H., Rosen C.F., et al. Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res 2011, 63:1091-1097.
191. Eder L., Shanmugarajah S., Thavaneswaran A., Chandran V., Rosen C.F., Cook R.J., et al. The association between smoking and the development of psoriatic arthritis among psoriasis patients. Ann Rheum Dis 2012, 71:219-224.
192. Li W., Han J., Qureshi A.A. Smoking and risk of incident psoriatic arthritis in US women. Ann Rheum Dis 2012, 71:804-808.
193. Tillett W., Jadon D., Shaddick G., Cavill C., Korendowych E., de Vries C.S., et al. Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. Ann Rheum Dis 2013, 72:1358-1361.
194. Bremander A., Jacobsson L.T., Bergman S., Haglund E., Löfvendahl S., Petersson I.F. Smoking is associated with a worse self-reported health status in patients with psoriatic arthritis: data from a Swedish population-based cohort. Clin Rheumatol 2014, [Epub ahead of print].
195. Højgaard P., Glintborg B., Hetland M.L., Hansen T.H., Lage-Hansen P.R., Petersen M.H., et al. Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Ann Rheum Dis 2014, [Epub ahead of print]. 10.1136/annrheumdis-2014-205389.
196. Miller S., Bawa S. The effect of smoking on treatment response and drug survival in psoriatic arthritis patients treated with their first anti-TNFa drug: a single-Centre restrospective analysis [abstract]. Ann Rheum Dis 2013, 72:686.
197. Fagerli K.M., Lie E., van der Heijde D., Heiberg M.S., Lexberg A.S., Rødevand E., et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014, 73:132-137.
198. Tablazon I.L., Al-Dabagh A., Davis S.A., Feldman S.R. Risk of cardiovascular disorders in psoriasis patients: current and future. Am J Clin Dermatol 2013, 14:1-7.
199. Katsiki N., Anagnostis P., Athyros V.G., Karagiannis A., Mikhailidis D.P. Psoriasis and vascular risk: an update. Curr Pharm Des 2014, [Epub ahead of print].
200. Grady D., Ernster V.L., Stillman L., Greenspan J. Smokeless tobacco use prevents aphthous stomatitis. Oral Surg Oral Med Oral Pathol 1992, 74:463-465.
201. Krause I., Rosen Y., Kaplan I., Milo G., Guedj D., Molad Y., et al. Recurrent aphthous stomatitis in Behçet's disease: clinical features and correlation with systemic disease expression and severity. J Oral Pathol Med 1999, 28:193-196.
202. Salonen L., Axéll T., Helldén L. Occurrence of oral mucosal lesions, the influence of tobacco habits and an estimate of treatment time in an adult Swedish population. J Oral Pathol Med 1990, 19:170-176.
203. Rizvi S.W., McGrath H. The therapeutic effect of cigarette smoking on oral/genital aphthosis and other manifestations of Behçet's disease. Clin Exp Rheumatol 2001, 19:S77-S78.
204. Soy M., Erken E., Konca K., Ozbek S. Smoking and Behçet's disease. Clin Rheumatol 2000, 19:508-509.
205. Aramaki K., Kikuchi H., Hirohata S. HLA-B51 and cigarette smoking as risk factors for chronic progressive neurological manifestations in Behçet's disease. Mod Rheumatol 2007, 17:81-82.
206. Özer H.T., Günesaçar R., Dinkçi S., Özbalkan Z., Yildiz F., Erken E. The impact of smoking on clinical features of Behçet's disease patients with glutathione S-transferase polymorphisms. Clin Exp Rheumatol 2012, 30:S14-S17.
207. Kaklamani V.G., Tzonou A., Markomichelakis N., Papazoglou S., Kaklamanis P.G. The effect of smoking on the clinical features of Adamantiades-Behçet's disease. Adv Exp Med Biol 2003, 528:323-327.
208. Kaklamani V.G., Markomichelakis N., Kaklamanis P.G. Could nicotine be beneficial for behçet's disease?. Clin Rheumatol 2002, 21:341-342.
209. Ciancio G., Colina M., La Corte R., Lo Monaco A., De Leonardis F., Trotta F., et al. Nicotine-patch therapy on mucocutaneous lesions of Behcet's disease: a case series. Rheumatology (Oxford) 2010, 49:501-504.
210. Scheid P., Bohadana A., Martinet Y. Nicotine patches for aphthous ulcers due to Behçet's syndrome. N Engl J Med 2000, 343:1816-1817.
211. Kalayciyan A., Orawa H., Fimmel S., Perschel F.H., González J.B., Fitzner R.G., et al. Nicotine and biochanin A, but not cigarette smoke, induce anti-inflammatory effects on keratinocytes and endothelial cells in patients with Behçet's disease. J Invest Dermatol 2007, 127:81-89.
212. Ingram J.R. Nicotine: does it have a role in the treatment of skin disease?. Postgrad Med J 2009, 85:196-201.
213. Bilgin A.B., Turkoglu E.B., Ilhan H.D., Unal M., Apaydin K.C. Is smoking a risk factor in ocular behçet disease?. Ocul Immunol Inflamm 2014, [Epub ahead of print].
214. Kolar P. Risk factors for central and branch retinal vein occlusion: a meta-analysis of published clinical data. J Ophthalmol 2014, 2014:724780.
215. Tsokos G.C. Systemic lupus erythematosus. N Engl J Med 2011, 365:2110-2121.
216. Miot H.A., Bartoli Miot L.D., Haddad G.R. Association between discoid lupus erythematosus and cigarette smoking. Dermatology 2005, 211:118-122.
217. Koskenmies S., Jarvinen T.M., Onkamo P., Panelius J., Tuovinen U., Hasan T., et al. Clinical and laboratory characteristics of Finnish lupus erythematosus patients with cutaneous manifestations. lupus 2008, 17:337-347.
218. Boeckler P., Cosnes A., Frances C., Hedelin G., Lipsker D. Association of cigarette smoking but not alcohol consumption with cutaneous lupus erythematosus. Arch Dermatol 2009, 145:1012-1016.
219. Böckle B.C., Sepp N.T. Smoking is highly associated with discoid lupus erythematosus and lupus erythematosus tumidus: analysis of 405 patients. Lupus 2014.
220. Kuhn A., Sigges J., Biazar C., Ruland V., Patsinakidis N., Landmann A., et al. Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. Br J Dermatol 2014, 171:571-579.
221. Piette E.W., Foering K.P., Chang A.Y., Okawa J., Ten Have T.R., Feng R., et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol 2012, 148:317-322.
222. Turchin I., Bernatsky S., Clarke A.E., St-Pierre Y., Pineau C.A. Cigarette smoking and cutaneous damage in systemic lupus erythematosus. J Rheumatol 2009, 36:2691-2693.
223. Hardy C.J., Palmer B.P., Muir K.R., Sutton A.J., Powell R.J. Smoking history, alcohol consumption, and systemic lupus erythematosus: a case-control study. Ann Rheum Dis 1998, 57:451-455.
224. Ghaussy N.O., Sibbitt W.L., Qualls C.R. Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: a case-control study. J Rheumatol 2001, 28:2449-2453.
225. Costenbader K.H., Kim D.J., Peerzada J., Lockman S., Nobles-Knight D., Petri M., et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 2004, 50:849-857.
226. Takvorian S.U., Merola J.F., Costenbader K.H. Cigarette smoking, alcohol consumption and risk of systemic lupus erythematosus. Lupus 2014, 23:537-544.
227. Bourré-Tessier J., Peschken C.A., Bernatsky S., Joseph L., Clarke A.E., Fortin P.R., et al. Canadian network for improved outcomes in systemic lupus erythematosus 1000 Canadian faces of lupus investigators, pineau CA. Association of smoking with cutaneous manifestations in systemic lupus erythematosus. Arthritis Care Res 2013, 65:1275-1280.
228. Ghaussy N.O., Sibbitt W., Bankhurst A.D., Qualls C.R. Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol 2003, 30:1215-1221.
229. Ekblom-Kullberg S., Kautiainen H., Alha P., Leirisalo-Repo M., Miettinen A., Julkunen H. Smoking, disease activity, permanent damage and dsDNA autoantibody production in patients with systemic lupus erythematosus. Rheumatol Int 2014, 34:341-345.
230. Ward M.M., Studenski S. Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking. Arch Intern Med 1992, 152:2082-2088.
231. Toloza S.M., Uribe A.G., McGwin G., Alarcón G.S., Fessler B.J., Bastian H.M., et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004, 50:3947-3957.
232. Ho K.T., Ahn C.W., Alarcón G.S., Baethge B.A., Tan F.K., Roseman J., et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 2005, 44:1303-1307.
233. Chasset F., Francès C., Barete S., Amoura Z., Arnaud L. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol 2015, 30.
234. Jewell M.L., McCauliffe D.P. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000, 42:983-987.
235. Dutz J., Werth V.P. Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma. J Invest Dermatol 2011, 131:1968-1970.
236. Schein J.R. Cigarette smoking and clinically significant drug interactions. Ann Pharmacother 1995, 29:1139-1148.
237. Rubin R.L., Hermanson T.M., Bedrick E.J., McDonald J.D., Burchiel S.W., Reed M.D., et al. Effect of cigarette smoke on autoimmunity in murine and human systemic lupus erythematosus. Toxicol Sci 2005, 87:86-96.
238. Freemer M.M., King T.E., Criswell L.A. Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann Rheum Dis 2006, 65:581-584.
239. Young K.A., Terrell D.R., Guthridge J.M., Kamen D.L., Gilkeson G.S., Karp D.R., et al. Smoking is not associated with autoantibody production in systemic lupus erythematosus patients, unaffected first-degree relatives, nor healthy controls. Lupus 2014, 23:360-369.
240. Arnson Y., Shoenfeld Y., Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010, 34:J258-J265.
241. Gustafsson J.T., Gunnarsson I., Källberg H., Pettersson S., Zickert A., Vikerfors A., et al. Cigarette smoking, antiphospholipid antibodies and vascular events in systemic lupus erythematosus. Ann Rheum Dis 2014.
242. Vikerfors A., Johansson A.B., Gustafsson J.T., Jönsen A., Leonard D., Zickert A., et al. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology (Oxford) 2013, 52:501-509.
243. Milo R., Miller A. Revised diagnostic criteria of multiple sclerosis. Autoimmun Rev 2014, 13(4-5):24-518.
244. World Health Organization Atlas of multiple sclerosis 2013.
245. Koch-Henriksen N., Sørensen P.S. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010, 9(5):520-532.
246. Milo R., Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010, 9(5):A387-A394.
247. Sawcer S., Franklin R.J.M., Ban M. Multiple sclerosis genetics. Lancet Neurol 2014, 13(7):700-709.
248. Belbasis L., Bellou V., Evangelou E., Ioannidis J.P.A., Tzoulaki I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol 2015, 14(3):263-273.
249. Versini M., Jeandel P.-Y., Rosenthal E., Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev 2014, 13(9):981-1000.
250. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296(23):2832-2838.
251. Hernán M.A., Olek M.J., Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol 2001, 154(1):69-74.
252. Riise T., Nortvedt M.W., Ascherio A. Smoking is a risk factor for multiple sclerosis. Neurology 2003, 61(8):1122-1124.
253. Mikaeloff Y., Caridade G., Tardieu M., Suissa S. Parental smoking at home and the risk of childhood-onset multiple sclerosis in children. Brain 2007, 130(10):2589-2595.
254. Sundström P., Nyström L., Hallmans G. Smoke exposure increases the risk for multiple sclerosis. Eur J Neurol 2008, 15(6):579-583.
255. Palacios N., Alonso A., Brønnum-Hansen H., Ascherio A. Smoking and increased risk of multiple sclerosis: parallel trends in the sex ratio reinforce the evidence. Ann Epidemiol 2011, 21(7):536-542.
256. Maghzi A.-H., Etemadifar M., Heshmat-Ghahdarijani K., Moradi V., Nonahal S., Ghorbani A., et al. Cigarette smoking and the risk of multiple sclerosis: a sibling case-control study in Isfahan, Iran. Neuroepidemiology 2011, 37(3-4):238-242.
257. Ramagopalan S.V., Lee J.D., Yee I.M., Guimond C., Traboulsee A.L., Ebers G.C., et al. Association of smoking with risk of multiple sclerosis: a population-based study. J Neurol 2013, 260(7):1778-1781.
258. Hedström A.K., Hillert J., Olsson T., Alfredsson L. Smoking and multiple sclerosis susceptibility. Eur J Epidemiol 2013, 28(11):867-874.
259. O'Gorman C., Bukhari W., Todd A., Freeman S., Broadley S.A. Smoking increases the risk of multiple sclerosis in Queensland, Australia. J Clin Neurosci 2014, 21(10):1730-1733.
260. Hedström A.K., Bäärnhielm M., Olsson T., Alfredsson L. Exposure to environmental tobacco smoke is associated with increased risk for multiple sclerosis. Mult Scler 2011, 17(7):788-793.
261. Hedstrom A., Olsson T., Alfredsson L. Smoking is a major preventable risk factor for multiple sclerosis. Mult Scler J 2015, 12.
262. O'Gorman C., Broadley S.A. Smoking and multiple sclerosis: evidence for latitudinal and temporal variation. J Neurol 2014, 261(9):1677-1683.
263. Hedström A.K., Sundqvist E., Bäärnhielm M., Nordin N., Hillert J., Kockum I., et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain 2011, 134(Pt 3):653-664.
264. Hedström A.K., Bomfim I.L., Barcellos L.F., Briggs F., Schaefer C., Kockum I., et al. Interaction between passive smoking and two HLA genes with regard to multiple sclerosis risk. Int J Epidemiol 2014, 43(6):1791-1798.
265. Hedstrom A.K., Baarnhielm M., Olsson T., Alfredsson L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 2009, 73(9):696-701.
266. Odoardi F., Sie C., Streyl K., Ulaganathan V.K., Schläger C., Lodygin D., et al. T cells become licensed in the lung to enter the central nervous system. Nature 2012, 488(7413):675-679.
267. Hernán M.A., Jick S.S., Logroscino G., Olek M.J., Ascherio A., Jick H. Cigarette smoking and the progression of multiple sclerosis. Brain 2005, 128(Pt 6):1461-1465.
268. Koch M., van Harten A., Uyttenboogaart M., De Keyser J. Cigarette smoking and progression in multiple sclerosis. Neurology 2007, 69(15):1515-1520.
269. Mandia D., Ferraro O.E., Nosari G., Montomoli C., Zardini E., Bergamaschi R. Environmental factors and multiple sclerosis severity: a descriptive study. Int J Environ Res Public Health 2014, 11(6):6417-6432.
270. Munger K.L., Fitzgerald K.C., Freedman M.S., Hartung H.-P., Miller D.H., Montalban X., et al. No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. Neurology 2015.
271. Di Pauli F., Reindl M., Ehling R., Schautzer F., Gneiss C., Lutterotti A., et al. Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult Scler 2008, 14(8):1026-1030.
272. Sundström P., Nyström L. Smoking worsens the prognosis in multiple sclerosis. Mult Scler 2008, 14(8):1031-1035.
273. Pittas F., Ponsonby A.-L., Mei I.A.F., Taylor B.V., Blizzard L., Groom P., et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J Neurol 2009, 256(4):577-585.
274. Healy B.C., Ali E.N., Guttmann C.R.G., Chitnis T., Glanz B.I., Buckle G., et al. Smoking and disease progression in multiple sclerosis. Arch Neurol 2009, 66(7):858-864.
275. Zivadinov R., Weinstock-Guttman B., Hashmi K., Abdelrahman N., Stosic M., Dwyer M., et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology 2009, 73(7):504-510.
276. D'hooghe M.B., Haentjens P., Nagels G., De Keyser J. Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis. Eur J Neurol 2012, 19(4):616-624.
277. Roudbari S.A., Ansar M.M., Yousefzad A. Smoking as a risk factor for development of secondary progressive multiple sclerosis: a study in IRAN, Guilan. J Neurol Sci 2013, 330(1-2):52-55.
278. Arikanoglu A., Shugaiv E., Tüzün E., Eraksoy M. Impact of cigarette smoking on conversion from clinically isolated syndrome to clinically definite multiple sclerosis. Int J Neurosci 2013, 123(7):476-479.
279. Ozcan M.E., Ince B., Bingöl A., Ertürk S., Altinöz M.A., Karadeli H.H., et al. Association between smoking and cognitive impairment in multiple sclerosis. Neuropsychiatr Dis Treat 2014, 10:1715-1719.
280. Weiland T.J., Hadgkiss E.J., Jelinek G.A., Pereira N.G., Marck C.H., van der Meer D.M. The association of alcohol consumption and smoking with quality of life, disability and disease activity in an international sample of people with multiple sclerosis. J Neurol Sci 2014, 336(1-2):211-219.
281. Durhan G., Diker S., Has A.C., Karakaya J., Kurne A.T., Karabudak R., et al. Assessment of the effect of cigarette smoking on regional brain volumes and lesion load in patients with clinically isolated syndrome. Int J Neurosci 2015, 3:1-7.
282. Ramanujam R., Hedström A.-K., Manouchehrinia A., Alfredsson L., Olsson T., Bottai M., et al. Effect of smoking cessation on multiple sclerosis prognosis. JAMA Neurol 2015, 72(10):1.
283. Horakova D., Zivadinov R., Weinstock-Guttman B., Havrdova E., Qu J., Tamaño-Blanco M., et al. Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study.Editor Fujinami R.S. PLoS One 2013, 8(1).
284. Manouchehrinia A., Weston M., Tench C.R., Britton J., Constantinescu C.S. Tobacco smoking and excess mortality in multiple sclerosis: a cohort study. J Neurol Neurosurg Psychiatry 2014, 85(10):1091-1095.
285. Turner A.P., Hartoonian N., Maynard C., Leipertz S.L., Haselkorn J.K. Smoking and physical activity: examining health behaviors and 15-year mortality among individuals with multiple sclerosis. Arch Phys Med Rehabil 2015, 96(3):402-409.
286. Jick S.S., Li L., Falcone G.J., Vassilev Z.P., Wallander M.-A. Epidemiology of multiple sclerosis: results from a large observational study in the UK. J Neurol 2015, 262(9):2033-2041.
287. Sena A., Bendtzen K., Cascais M.J., Pedrosa R., Ferret-Sena V., Campos E. Influence of apolipoprotein E plasma levels and tobacco smoking on the induction of neutralising antibodies to interferon-beta. J Neurol 2010, 257(10):1703-1707.
288. Hedström A.K., Ryner M., Fink K., Fogdell-Hahn A., Alfredsson L., Olsson T., et al. Smoking and risk of treatment-induced neutralizing antibodies to interferon β-1a. Mult Scler 2014, 20(4):445-450.
289. Yadav S.K., Mindur J.E., Ito K., Dhib-Jalbut S. Advances in the immunopathogenesis of multiple sclerosis. Curr Opin Neurol 2015, 28(3):206-219.
290. Correale J., Farez M.F. Smoking worsens multiple sclerosis prognosis: two different pathways are involved. J Neuroimmunol 2015, 281:23-34.
291. Gao Z., Nissen J.C., Ji K., Tsirka S.E. The experimental autoimmune encephalomyelitis disease course is modulated by nicotine and other cigarette smoke components. PLoS One 2014, 9(9).
292. Khanna A., Guo M., Mehra M., Royal W. Inflammation and oxidative stress induced by cigarette smoke in Lewis rat brains. J Neuroimmunol 2013, 254(1-2):69-75.
293. Carbone M., Neuberger J.M. Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol 2014, 60:210-223.
294. Kaplan M.M., Gershwin M.E. Primary biliary cirrhosis. N Engl J Med 2005, 353:1261-1273.
295. Smyk D.S., Rigopoulou E.I., Muratori L., Burroughs A.K., Bogdanos D.P. Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. Ann Hepatol 2012, 11:7-14.
296. Hirschfield G.M., Chapman R.W., Karlsen T.H., Lammert F., Lazaridis K.N., Mason A.L. The genetics of complex cholestatic disorders. Gastroenterology 2013, 144:1357-1374.
297. Juran B.D., Lazaridis K.N. Environmental factors in primary biliary cirrhosis. Semin Liver Dis 2014, 34:265-272.
298. Lammert C., Nguyen D.L., Juran B.D., Schlicht E., Larson J.J., Atkinson E.J., et al. Questionnaire based assessment of risk factors for primary biliary cirrhosis. Dig Liver Dis 2013, 45:589-594.
299. Gershwin M.E., Selmi C., Worman H.J., Gold E.B., Watnik M., Utts J., et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005, 42:1194-1202.
300. Parikh-Patel A., Gold E.B., Worman H., Krivy K.E., Gershwin M.E. Risk factors for primary biliary cirrhosis in a cohort of patients from the United States. Hepatology 2001, 33:16-21.
301. Corpechot C., Chrétien Y., Chazouillères O., Poupon R. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol 2010, 53:162-169.
302. Cookson S., Constantini P.K., Clare M., et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999, 30:851-856.
303. Czaja A.J., Cookson S., Constantini P.K., Clare M., Underhill J.A., Donaldson P.T. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999, 117:645-652.
304. Agarwal K., Czaja A.J., Jones D.E., Donaldson P.T. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility autoimmune hepatitis. Hepatology 2000, 31:49-53.
305. Heneghan M.A., Yeoman A.D., Verma S., Smith A.D., Longhi M.S. Autoimmune hepatitis. Lancet 2013, 382:1433-1444.
306. Hirschfield G.M., Karlsen T.H., Lindor K.D., Adams D.H. Primary sclerosing cholangitis. Lancet 2013, 382:1587-1599.
307. Andersen I.M., Tengesdal G., Lie B.A., Boberg K.M., Karlsen T.H., Hov J.R. Effects of coffee consumption, smoking, and hormones on risk for primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2014, 12:1019-1028.
308. Mitchell S.A., Thyssen M., Orchard T.R., Jewell D.P., Fleming K.A., Chapman R.W. Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut 2002, 51:567-573.
309. Loftus E.V., Sandborn W.J., Tremaine W.J., Mahoney D.W., Zinsmeister A.R., Offord K.P., et al. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology 1996, 110:1496-1502.
310. Siebold J. Scleroderma. Kelley's textbook of rheumatology 2005, Elsevier, Philadelphia. 7th ed. E. Harris, R. Budd, G. Firestein, M. Genovese, J. Sergent, S. Ruddy (Eds.).
311. LeRoy E.C., Black C., Fleischmajer R., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
312. Chaudhary P., Chen X., Assassi S., Gorlova O., Draeger H., Harper B.E., et al. Cigarette smoking is not a risk factor for systemic sclerosis. Arthritis Rheum 2011, 63:3098-3102.
313. Hudson M., Lo E., Lu Y., Hercz D., Baron M., Steele R. Cigarette smoking in patients with systemic sclerosis. Arthritis Rheum 2011, 63:230-238.
314. Hissaria P., Lester S., Hakendorf P., Woodman R., Patterson K., Hill C., et al. Survival in scleroderma: results from the population-based south Australian Register. Intern Med J 2011, 41:381-390.
315. Orgiazzi J. Thyroid autoimmunity. Presse Med 2012 Dec, 41(12 P 2):25-e611.
316. Antonelli A., Ferrari S.M., Corrado A., et al. Autoimmune thyroid disorders. Autoimmun Rev 2015 Feb, 14(2):174-180.
317. Jacobson D.L., Gange S.J., Rose N.R., Graham N.M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997, 84(3):223-243.
318. McLeod D.S., Cooper D.S. The incidence and prevalence of thyroid autoimmunity. Endocrine 2012, 42(2):252-265.
319. Tunbridge W.M., Evered D.C., Hall R., Appleton D., Brewis M., Clark F., et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977, 7(6):481-493.
320. Antonelli A., Ferrari S.M., Giuggioli D., Ferrannini E., Ferri C., Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 2014, 13(3):272-280.
321. Antonelli A., Ferrari S.M., Corrado A., Franceschini S.S., Gelmini S., Ferrannini E., et al. Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete α (CXCL10) and β (CCL2) chemokines under the influence of cytokines that are modulated by PPARγ. Autoimmun Rev 2014, 13(11):1160-1166.
322. Tomer Y., Davies T.F. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr Rev 2003, 24(5):694-717.
323. Hansen P.S., Brix T.H., Iachine I., Kyvik K.O., Hegedüs L. The relative importance of genetic and environmental effects for the early stages of thyroid autoimmunity: a study of healthy Danish twins. Eur J Endocrinol 2006, 154(1):29-38.
324. Brix T.H., Hegedus L. Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin Endocrinol (Oxf) 2012, 76(4):457-464.
325. Simmonds M.J. GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis. Nat Rev Endocrinol 2013, 9(5):277-287.
326. Tanda M.L., Piantanida E., Lai A., Lombardi V., Dalle Mule I., Liparulo L., et al. Thyroid autoimmunity and environment. Horm Metab Res 2009, 41(6):436-442.
327. Prummel M.F., Wiersinga W.M. Smoking and risk of Graves' disease. JAMA 1993, 269(4):479-482.
328. Bartalena L., Marcocci C., Tanda M.L., Manetti L., Dell'Unto E., Bartolomei M.P., et al. Cigarette smoking and treatment outcomes in graves ophthalmopathy. Ann Intern Med 1998, 129(8):632-635.
329. Wiersinga W.M. Smoking and thyroid. Clin Endocrinol (Oxf) 2013, 79(2):145-151.
330. Nizzi E., Irony-Tur-Sinai M., Lory O., Orr-Urtreger A., Lavi E., Brenner T. Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. J Immunol 2009 Nov, 183(10):6681-6688.
331. Bartalena L., Martino E., Marcocci C., Bogazzi F., Panicucci M., Velluzzi F., et al. More on smoking habits and Graves' ophthalmopathy. J Endocrinol Invest 1989, 12(10):733-737.
332. Ericsson U.B., Lindgärde F. Effects of cigarette smoking on thyroid function and the prevalence of goitre, thyrotoxicosis and autoimmune thyroiditis. J Intern Med 1991 Jan, 229(1):67-71.
333. Fukata S., Kuma K., Sugawara M. Relationship between cigarette smoking and hypothyroidism in patients with Hashimoto's thyroiditis. J Endocrinol Invest 1996, 19(9):607-612.
334. Vestergaard P. Smoking and thyroid disorders-a meta-analysis. Eur J Endocrinol 2002, 146(2):153-161.
335. Strieder T.G., Prummel M.F., Tijssen J.G., Endert E., Wiersinga W.M. Risk factors for and prevalence of thyroid disorders in a cross-sectional study among healthy female relatives of patients with autoimmune thyroid disease. Clin Endocrinol (Oxf) 2003, 59(3):396-401.
336. Belin R.M., Astor B.C., Powe N.R., Ladenson P.W. Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the third national health and nutrition examination survey (NHANES III). J Clin Endocrinol Metab 2004, 89(12):6077-6086.
337. Galanti M.R., Cnattingius S., Granath F., Ekbom-Schnell A., Ekbom A. Smoking and environmental iodine as risk factors for thyroiditis among parous women. Eur J Epidemiol 2007, 22(7):467-472.
338. Pedersen I.B., Laurberg P., Knudsen N., Jørgensen T., Perrild H., Ovesen L., et al. Smoking is negatively associated with the presence of thyroglobulin autoantibody and to a lesser degree with thyroid peroxidase autoantibody in serum: a population study. Eur J Endocrinol 2008, 158(3):367-373.
339. Effraimidis G., Tijssen J.G., Wiersinga W.M. Discontinuation of smoking increases the risk for developing thyroid peroxidase antibodies and/or thyroglobulin antibodies: a prospective study. J Clin Endocrinol Metab 2009, 94(4):1324-1328.
340. Effraimidis G., Strieder T.G., Tijssen J.G., Wiersinga W.M. Natural history of the transition from euthyroidism to overt autoimmune hypo- or hyperthyroidism: a prospective study. Eur J Endocrinol 2011, 164(1):107-113.
341. Carlé A., Bülow Pedersen I., Knudsen N., Perrild H., Ovesen L., Banke Rasmussen L., et al. Smoking cessation is followed by a sharp but transient rise in the incidence of overt autoimmune hypothyroidism - a population-based, case-control study. Clin Endocrinol (Oxf) 2012, 77(5):764-772.
342. Rendina D., De Palma D., De Filippo G., De Pascale F., Muscariello R., Ippolito R., et al. Prevalence of simple nodular goiter and Hashimoto's thyroiditis in current, previous, and never smokers in a geographical area with mild iodine deficiency. Horm Metab Res 2015, 47(3):214-219.
343. Balazs C., Stenszky V., Farid N.R. Association between Graves' ophthalmopathy and smoking. Lancet 1990, 336(8717):754.
344. Tellez M., Cooper J., Edmonds C. Graves' ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin Endocrinol (Oxf) 1992, 36(3):291-294.
345. Vestergaard P., Rejnmark L., Weeke J., Hoeck H.C., Nielsen H.K., Rungby J., et al. Smoking as a risk factor for Graves' disease, toxic nodular goiter, and autoimmune hypothyroidism. Thyroid 2002, 12(1):69-75.
346. Holm I.A., Manson J.E., Michels K.B., Alexander E.K., Willett W.C., Utiger R.D. Smoking and other lifestyle factors and the risk of Graves' hyperthyroidism. Arch Intern Med 2005, 165(14):1606-1611.
347. Berglund J., Ericsson U.B., Hallengren B. Increased incidence of thyrotoxicosis in Malmö during the years 1988-1990 as compared to the years 1970-1974. J Intern Med 1996, 239(1):57-62.
348. Glinoer D., de Nayer P., Bex M. Belgian collaborative study group on Graves' disease. Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 2001, 144(5):475-483.
349. Nedrebo B.G., Holm P.I., Uhlving S., Sorheim J.I., Skeie S., Eide G.E., et al. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur J Endocrinol 2002, 147(5):583-589.
350. Orgiazzi J., Madec A.M. Reduction of the risk of relapse after withdrawal of medical therapy for Graves' disease. Thyroid 2002, 12(10):849-853.
351. Träisk F., Tallstedt L., Abraham-Nordling M., Andersson T., Berg G., Calissendorff J., et al. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 2009, 94(10):3700-3707.
352. Hou X., Li Y., Li J., Wang W., Fan C., Wang H., et al. Development of thyroid dysfunction and autoantibodies in Graves' multiplex families: an eight-year follow-up study in Chinese Han pedigrees. Thyroid 2011, 21(12):1353-1358.
353. Anagnostis P., Adamidou F., Polyzos S.A., Katergari S., Karathanasi E., Zouli C., et al. Predictors of long-term remission in patients with Graves' disease: a single center experience. Endocrine 2013, 44(2):448-453.
354. Regensburg N.I., Wiersinga W.M., Berendschot T.T., Saeed P., Mourits M.P. Effect of smoking on orbital fat and muscle volume in Graves' orbitopathy. Thyroid 2011, 21(2):177-181.
355. Metcalfe R.A., Weetman A.P. Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy. Clin Endocrinol (Oxf) 1994, 40(1):67-72.
356. Burch H.B., Lahiri S., Bahn R.S., Barnes S. Superoxide radical production stimulates retroocular fibroblast proliferation in Graves' ophthalmopathy. Exp Eye Res 1997, 65(2):311-316.
357. Bartalena L., Tanda M.L., Piantanida E., Lai A. Oxidative stress and Graves' ophthalmopathy: in vitro studies and therapeutic implications. Biofactors 2003, 19(3-4):155-163.
358. Tsai C.C., Cheng C.Y., Liu C.Y., Kao S.C., Kau H.C., Hsu W.M., et al. Oxidative stress in patients with Graves' ophthalmopathy: relationship between oxidative DNA damage and clinical evolution. Eye (Lond) 2009, 23(8):1725-1730.
359. Yoon J.S., Lee H.J., Chae M.K., Lee S.Y., Lee E.J. Cigarette smoke extract-induced adipogenesis in Graves' orbital fibroblasts is inhibited by quercetin via reduction in oxidative stress. J Endocrinol 2013, 216(2):145-156.
360. Chng C.L., OF L., Chew C.S., Peh Y.P., Fook-Chong S.M., Seah L.L., et al. Hypoxia increases adipogenesis and affects adipocytokine production in orbital fibroblasts-a possible explanation of the link between smoking and Graves' ophthalmopathy. Int J Ophthalmol 2014, 7(3):403-407.
361. Mack W.P., Stasior G.O., Cao H.J., Stasior O.G., Smith T.J. The effect of cigarette smoke constituents on the expression of HLA-DR in orbital fibroblasts derived from patients with Graves ophthalmopathy. Ophthal Plast Reconstr Surg 1999, 15(4):260-271.
362. Wakelkamp I.M., Gerding M.N., van der Meer J.W., Prummel M.F., Wiersinga W.M. Smoking and disease severity are independent determinants of serum adhesion molecule levels in Graves' ophthalmopathy. Clin Exp Immunol 2002, 127(2):316-320.
363. Bufalo N.E., Santos R.B., Cury A.N., Andrade R.A., Morari J., Morari E.C., et al. Genetic polymorphisms associated with cigarette smoking and the risk of graves' disease. Clin Endocrinol (Oxf) 2008, 68(6):982-987.
364. Planck T., Shahida B., Sjögren M., Groop L., Hallengren B., Lantz M. Association of BTG2, CYR61, ZFP36, and SCD gene polymorphisms with Graves' disease and ophthalmopathy. Thyroid 2014, 24(7):1156-1161.
365. Planck T., Shahida B., Parikh H., Ström K., Asman P., Brorson H., et al. Smoking induces overexpression of immediate early genes in active Graves' ophthalmopathy. Thyroid 2014, 24(10):1524-1532.
366. Atkinson M.A., Eisenbarth G.S., Michels A.W. Type 1 diabetes. Lancet 2014, 383(9911):69-82.
367. Davidson A., Diamond B. Autoimmune diseases. N Engl J Med 2001, 345(5):340-350.
368. Battaglia M. Experiments by nature: lessons on type 1 diabetes. Tissue Antigens 2014, 83(1):1-9.
369. Roep B.O., Tree T.I. Immune modulation in humans: implications for type 1 diabetes mellitus. Nat Rev Endocrinol 2014, 10(4):229-242.
370. Kawasaki E. Type 1 diabetes and autoimmunity. Clin Pediatr Endocrinol 2014, 23(4):99-105.
371. Antonelli A., Ferrari S.M., Corrado A., Ferrannini E., Fallahi P. CXCR3, CXCL10 and type 1 diabetes. Cytokine Growth Factor Rev 2014, 25(1):57-65.
372. Antonelli A., Fallahi P., Ferrari S.M., Pupilli C., d'Annunzio G., Lorini R., et al. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed type 1 diabetes: a longitudinal study. Diabet Med 2008, 25(11):1349-1353.
373. Antonelli A., Baj G., Marchetti P., Fallahi P., Surico N., Pupilli C., et al. Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets. Diabetes 2001, 50(5):985-991.
374. Concannon P., Rich S.S., Nepom G.T. Genetics of type 1a diabetes. N Engl J Med 2009, 360(16):1646-1654.
375. Stankov K., Benc D., Draskovic D. Genetic and epigenetic factors in etiology of diabetes mellitus type 1. Pediatrics 2013, 132(6):1112-1122.
376. Rønningen K.S. Type 1 diabetes: prospective cohort studies for identification of the environmental trigger. Arch Immunol Ther Exp (Warsz) 2013, 61(6):459-468.
377. Zipris D. The interplay between the gut microbiota and the immune system in the mechanism of type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2013, 20(4):265-270.
378. Stene L.C., Gale E.A. The prenatal environment and type 1 diabetes. Diabetologia 2013, 56(9):1888-1897.
379. Craig M.E., Nair S., Stein H., Rawlinson W.D. Viruses and type 1 diabetes: a new look at an old story. Pediatr Diabetes 2013, 14(3):149-158.
380. Sipetic S.B., Vlajinac H.D., Kocev N.I., Marinkovic J.M., Radmanovic S.Z., Bjekic M.D. The Belgrade childhood diabetes study: a multivariate analysis of risk determinants for diabetes. Eur J Public Health 2005, 15(2):117-122.
381. Wahlberg J., Vaarala O., Ludvigsson J., ABIS study group Asthma and allergic symptoms and type 1 diabetes-related autoantibodies in 2.5-yr-old children. Pediatr Diabetes 2011, 12(7):604-610.
382. Stene L.C., Barriga K., Norris J.M., Hoffman M., Erlich H.A., Eisenbarth G.S., et al. Perinatal factors and development of islet autoimmunity in early childhood: the diabetes autoimmunity study in the young. Am J Epidemiol 2004, 160(1):3-10.
383. Rosenbauer J., Herzig P., Kaiser P., Giani G. Early nutrition and risk of type 1 diabetes mellitus-a nationwide case-control study in preschool children. Exp Clin Endocrinol Diabetes 2007, 115(8):502-508.
384. Wadsworth E.J., Shield J.P., Hunt L.P., Baum J.D. A case-control study of environmental factors associated with diabetes in the under 5s. Diabet Med 1997, 14(5):390-396.
385. Toschke A.M., Ehlin A., Koletzko B., Montgomery S.M. Paternal smoking is associated with a decreased prevalence of type 1 diabetes mellitus among offspring in two national British birth cohort studies (NCDS and BCS70). J Perinat Med 2007, 35(1):43-47.
386. Johansson A., Hermansson G., Ludvigsson J., ABIS Study Group Tobacco exposure and diabetes-related autoantibodies in children: results from the ABIS study. Ann N Y Acad Sci 2008, 1150:197-199.
387. Dahlquist G., Källén B. Maternal-child blood group incompatibility and other perinatal events increase the risk for early-onset type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1992, 35(7):671-675.
388. Marshall A.L., Chetwynd A., Morris J.A., Placzek M., Smith C., Olabi A., et al. Type 1 diabetes mellitus in childhood: a matched case control study in Lancashire and Cumbria, UK. Diabet Med 2004, 21(9):1035-1040.
389. Svensson J., Carstensen B., Mortensen H.B. Borch-johnsen K; Danish study group of childhood diabetes. Early childhood risk factors associated with type 1 diabetes--is gender important?. Eur J Epidemiol 2005, 20(5):429-434.
390. Hathout E.H., Beeson W.L., Ischander M., Rao R., Mace J.W. Air pollution and type 1 diabetes in children. Pediatr Diabetes 2006, 7(2):81-87.
391. Skrodeniene E., Marciulionyte D., Padaiga Z., Jasinskiene E., Sadauskaite-Kuehne V., Ludvigsson J. Environmental risk factors in prediction of childhood prediabetes. Medicina (Kaunas) 2008, 44(1):56-63.
392. Olin J.W. Thromboangiitis obliterans (Buerger's disease). N Engl J Med 2000, 343(12):864-869.
393. Machado E.B., Gabriel S.E., Beard C.M., Michet C.J., O'Fallon W.M., Ballard D.J. A population-based case-control study of temporal arteritis: evidence for an association between temporal arteritis and degenerative vascular disease?. Int J Epidemiol 1989, 18(4):836-841.
394. Duhaut P., Pinede L., Demolombe-Rague S., Loire R., Seydoux D., Ninet J., et al. Giant cell arteritis and cardiovascular risk factors: a multicenter, prospective case-control study. Groupe de recherche sur l'artérite à cellules Géantes. Arthritis Rheum 1998, 41(11):1960-1965.
395. Larsson K., Mellström D., Nordborg E., Nordborg C., Odén A. Early menopause, low body mass index, and smoking are independent risk factors for developing giant cell arteritis. Ann Rheum Dis 2006, 65(4):529-532.
396. Jakobsson K., Jacobsson L., Warrington K., Matteson E.L., Liang K., Melander O., et al. Body mass index and the risk of giant cell arteritis: results from a prospective study. Rheumatology (Oxford) 2015, 54(3):433-440.
397. Kermani T.A., Schäfer V.S., Crowson C.S., Hunder G.G., Ytterberg S.R., Matteson E.L., et al. Cancer preceding giant cell arteritis: a case-control study. Arthritis Rheum 2010, 62(6):1763-1769.
398. Lane S.E., Watts R.A., Bentham G., Innes N.J., Scott D.G.I. Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum 2003, 48(3):814-823.
399. Beaudreuil S., Lasfargues G., Lauériere L., El Ghoul Z., Fourquet F., Longuet C., et al. Occupational exposure in ANCA-positive patients: a case-control study. Kidney Int 2005, 67(5):1961-1966.
400. Haubitz M., Woywodt A., de Groot K., Haller H., Goebel U. Smoking habits in patients diagnosed with ANCA associated small vessel vasculitis. Ann Rheum Dis 2005, 64(10):1500-1502.
401. Gonzalez-Gay M.A., Piñeiro A., Gomez-Gigirey A., Garcia-Porrua C., Pego-Reigosa R., Dierssen-Sotos T., et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004, 83(6):342-347.
402. Robson J.C., Kiran A., Maskell J., Hutchings A., Arden N., Dasgupta B., et al. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Ann Rheum Dis 2015, 74(1):129-135.
403. Mohammad A.J., Segelmark M. Association of cigarette smoking with organ damage in primary systemic vasculitis. Scand J Rheumatol 2011, 40(1):51-56.
404. Lega J.-C., Seror R., Fassier T., Aumaître O., Quere I., Pourrat J., et al. Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: a retrospective multicenter study. Semin Arthritis Rheum 2014, 43(5):681-688.
405. Benarous L, Terrier B, Puéchal X, Dunogué B, Cohen P, Le Jeunne C, et al. Tobacco differentially affects the clinical-biological phenotypes of ANCA-associated vasculitides. Clin Exp Rheumatol. Jan; 33(2 Suppl 89):S 116-21.
406. Maniaol A.H., Boldingh M., Brunborg C., Harbo H.F., Tallaksen C.M.E. Smoking and socio-economic status may affect myasthenia gravis. Eur J Neurol 2013, 20(3):453-460.
407. Gratton S.M., AM H., WJ F., BL L. Cigarette smoking and activities of daily living in ocular myasthenia gravis. J Neuroophthalmol 2015.
408. Snook J.A., Dwyer L., Lee-Elliott C., Khan S., Wheeler D.W., Nicholas D.S. Adult coeliac disease and cigarette smoking. Gut 1996, 39(1):60-62.
409. Vazquez H., Smecuol E., Flores D., Mazure R., Pedreira S., Niveloni S., et al. Relation between cigarette smoking and celiac disease: evidence from a case-control study. Am J Gastroenterol 2001, 96(3):798-802.
410. Suman S., Williams E.J., Thomas P.W., Surgenor S.L., Snook J.A. Is the risk of adult coeliac disease causally related to cigarette exposure?. Eur J Gastroenterol Hepatol 2003, 15(9):995-1000.
411. Austin A.S., Logan R.F.A., Thomason K., Holmes G.K.T. Cigarette smoking and adult coeliac disease. Scand J Gastroenterol 2002, 37(8):978-982.
412. Patel A.H., Loftus E.V., Murray J.A., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. Cigarette smoking and celiac sprue: a case-control study. Am J Gastroenterol 2001, 96(8):2388-2391.
413. Ludvigsson J.F., Nordenvall C., Järvholm B. Smoking, use of moist snuff and risk of celiac disease: a prospective study. BMC Gastroenterol 2014, 14:120.
414. Ludvigsson J.F., Ludvigsson J. Parental smoking and risk of coeliac disease in offspring. Scand J Gastroenterol 2005, 40(3):336-342.
415. Ludvigsson J.F., Montgomery S.M., Ekbom A. Smoking and celiac disease: a population-based cohort study. Clin Gastroenterol Hepatol 2005, 3(9):869-874.
416. Brenner S., Tur E., Shapiro J., Ruocco V., D'Avino M., Ruocco E., et al. Pemphigus vulgaris: environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire. Int J Dermatol 2001, 40(9):562-569.
417. Sullivan T.P., Elgart G.W., Kirsner R.S. Pemphigus and smoking. Int J Dermatol 2002, 41(8):528-530.
418. Valikhani M., Kavusi S., Chams-Davatchi C., Daneshpazhooh M., Barzegari M., Ghiasi M., et al. Pemphigus and associated environmental factors: a case-control study. Clin Exp Dermatol 2007, 32(3):256-260.
419. Valikhani M., Kavusi S., Chams-Davatchi C., Hallaji Z., Esmaili N., Ghandi N., et al. Impact of smoking on pemphigus. Int J Dermatol 2008, 47(6):567-570.
420. Mehta J.N., Martin A.G. A case of pemphigus vulgaris improved by cigarette smoking. Arch Dermatol 2000, 136(1):15-17.
421. Grando S.A., Dahl M.V. Nicotine and pemphigus. Arch Dermatol 2000, 136(10):1269.
422. Baron-Epel O., Shalata W., Hovell M.F. Waterpipe tobacco smoking in three Israeli adult populations. Isr Med Assoc J 2015, 17(5):282-287.
423. Hollan I., Dessein P.H., Ronda N., Wasko M.C., Svenungsson E., Agewall S., et al. Prevention of cardiovascular disease in rheumatoid arthritis. Autoimmun Rev 2015, 14(10):952-969.
424. Selmi C., Cantarini L., Kivity S., Dagaan A., Shovman O., Zandman-Goddard G., et al. The 2014 ACR annual meeting: a bird's eye view of autoimmunity in 2015. Autoimmun Rev 2015, 14(7):622-632.
425. Sela B.A. Time for setting a good example: physicians, quit smoking now. Isr Med Assoc J 2013, 15(7):379-381.
426. Marie I., Gehanno J.F., Bubenheim M., Duval-Modeste A.B., Joly P., Dominique S., et al. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. Autoimmun Rev 2014, 13(2):151-156.
427. Gómez-Puerta J.A., Gedmintas L., Costenbader K.H. The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis. Autoimmun Rev 2013, 12(12):1129-1135.
428. Sakkas L.I., Bogdanos D.P., Katsiari C., Platsoucas C.D. Anti-citrullinated peptides as autoantigens in rheumatoid arthritis-relevance to treatment. Autoimmun Rev 2014, 13(11):1114-1120.
429. Ben-Horin S., Kopylov U., Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014, 13(1):24-30.
430. Kiyohara C., Washio M., Horiuchi T., Tada Y., Asami T., Ide S., et al. Kobashi G; Kyushu Sapporo SLE (KYSS) study group. Cigarette smoking, N-acetyltransferase 2 polymorphisms and systemic lupus erythematosus in a Japanese population. Lupus 2009, 18(7):630-638.